Developments with experimental and investigational drugs for axial spondyloarthritis.

about

Developments with experimental and investigational drugs for axial spondyloarthritis.

Item

http://www.wikidata.org/entity/Q38676714

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Developments with experimental and investigational drugs for axial spondyloarthritis.

@en

type

Item

label

Developments with experimental and investigational drugs for axial spondyloarthritis.

@en

prefLabel

Developments with experimental and investigational drugs for axial spondyloarthritis.

@en

P1476

Developments with experimental and investigational drugs for axial spondyloarthritis.

@en

P2093

Gaëlle Clavel

http://www.w3.org/2001/XMLSchema#string

Johanna Sigaux

http://www.w3.org/2001/XMLSchema#string

Luca Semerano

http://www.w3.org/2001/XMLSchema#string

Marie-Christophe Boissier

http://www.w3.org/2001/XMLSchema#string

P2860

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants

The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis

HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Update on the therapeutic potential of PDE4 inhibitors.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

P304

833-842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1337744

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28562100

http://www.w3.org/2001/XMLSchema#string